Applications
Human neural tissue that works, and scales.
Intact neural tissue with midbrain-specific cell types, grown from any human iPSC line, including yours.
What the tissue is
Midbrain identity. Whole-tissue biology.
The patterning gives our organoids midbrain identity, so dopaminergic neurons are well represented. But the organoid is not a purified population.
It contains the full range of cell types found in neural tissue (neurons through glia) in their own cellular context, not isolated from it. There is no necrotic core, no rosette structure, and spontaneous activity stays synchronised across the whole organoid: the tissue is connected, not merely alive. Transcriptionally it correlates with human fetal midbrain at 0.78 (Pearson).
Whether a model is relevant to humans is decided by the tissue type, not by the brain region. That is what qualifies it for the work below, rather than its midbrain address. How the tissue is characterised
01Where it is applied
One platform, four questions.
With this platform, many different research questions can be addressed: from simple neurotoxicity screening to elaborate mechanism-of-action discovery and disease models. Each of these is either work we run today or work already carried into print.
Does your compound damage the tissue?
Neurotoxicity in human tissue, with selective loss distinguishable from general cytotoxicity.
Renner, Bruder et al., Frontiers in Molecular Neuroscience, 2021
What did your compound actually do?
Pathways, deposits and network activity, resolved to the single cell, in the same organoid.
Renner, Bruder et al., eLife, 2020
What about my own cell line?
Organoids grown from your own iPSC line, so the mutation and the genetic background are yours, not ours.
Does the platform extend beyond midbrain tissue?
Forebrain organoids and tumour assembloids, produced on the same automation.
Riedel, Bruder et al., Cancer Communications, 2025 · de Faria, Bruder et al., Nature Communications, 2025
Note that the oncology work uses forebrain rather than midbrain organoids. That is the point: the tissue identity changes, the automation, the plate format and the readouts do not. We stay deliberate about what we claim: midbrain organoids are what PEARL runs studies on today, and other tissue identities are demonstrated in the literature rather than offered from a catalogue.
02Toxicity screening
The cheapest failure is the earliest one.
Neural tissue is among the least forgiving tissue to damage, and the least able to recover from it. A compound that damages it has told you something decisive, in week five rather than in phase II.
Because the organoid holds several cell types at once, the readout separates two very different findings: general cytotoxicity, and the selective loss of one population while the rest of the tissue survives. Rotenone, an established dopaminergic toxin, strips tyrosine hydroxylase and MAP2 signal while nuclei remain: a pattern a viability number alone would never show you.
Dose–response runs in the plate the organoids grew in, and can be measured against a two-dimensional control in the same experiment. Cell-type-specific high-throughput toxicity testing in these organoids is published in Frontiers in Molecular Neuroscience (Renner, Bruder et al., 2021).
03Functional studies
Dead or alive is one bit of information.
Which pathways a compound intervenes in. Whether something accumulates or is deposited. What changes in the tissue follow exposure, and in which cells.
That last part matters more than it sounds. An averaged signal across a mixed tissue can hide an effect entirely: a compound that halves one population while sparing another looks like a modest change to a plate reader. We resolve to the single cell, which is where those effects actually live.
Single-cell resolution
Single-cell RNA sequencing for transcriptional state, and immunohistochemistry read cell by cell rather than as a whole-well average.
Pathway intervention
Marker panels chosen for the question at hand, imaged across the whole organoid rather than in a section of it.
Accumulation & deposition
Tissue clearing before acquisition means deposits are located in three dimensions, not inferred from a plane.
Network function
Calcium imaging of spontaneous, synchronised activity: whole-organoid, by quadrant and per cell.
The reproducibility of the process is what makes this possible. A neighbouring organoid from the same batch can be treated as a stand-in for the one just measured, so structural change, marker expression, transcriptional state and network activity read across organoids as reliably as within one. That also enables time-series designs: one organoid analysed at an early timepoint, a sibling from the same batch left to grow on to a later one.
04Your cell line
Send us your line. We make it reproducible.
The consistency comes from the process, not from one blessed cell line. Any human iPSC line can go in, including the one your programme is already built on.
Drug programmes are rarely line-agnostic. A target is validated in a particular donor background. A mutation of interest sits in a particular patient line. A comparison only means something against its own isogenic control. Sending that work to a platform that runs only its own material means getting an answer to a slightly different question from the one you asked.
The route into our organoids runs through iPSC-derived smNPCs rather than through a proprietary line, so the line you send is the line the tissue is grown from, with the same automation, the same plate format and the same readouts around it. Your mutation, your background, our reproducibility.
Isogenetically produced AMOs. AMOs with the Parkinson’s-specific mutation LRRK2-G2019S (right) show reduced neurite outgrowth compared to their isogenic wildtype control (left).
Our own worked example is a Parkinson’s model built on the LRRK2 mutation. It is in development: not a product, not published, and we would rather say that plainly than let a page imply otherwise. Talk to us about your line, or about that one.
Not sure if our organoids fit your question?
Tell us what you are trying to measure. We will tell you honestly whether our organoids are the right model for it.